Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Gontero P, Birtle A, Capoun O et al (2024) European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (TaT1 and Carcinoma in Situ)-A Summary of the 2024 guidelines Update. Eur Urol. Published Online August 17(24):S0302–2838. https://doi.org/10.1016/j.eururo.2024.07.027

Article  Google Scholar 

Compérat E, Larré S, Roupret M et al (2015) Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch Int J Pathol 466(5):589–594. https://doi.org/10.1007/s00428-015-1739-2

Article  Google Scholar 

Sylvester RJ, Rodríguez O, Hernández V et al (2021) European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder Cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for Grade: an update from the EAU NMIBC guidelines Panel. Eur Urol 79(4):480–488. https://doi.org/10.1016/j.eururo.2020.12.033

Article  PubMed  Google Scholar 

Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and Risk groups for Predicting recurrence, progression, and Disease-specific and overall survival in Non-muscle-invasive Stage Ta-T1 urothelial bladder Cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guérin. Eur Urol 69(1):60–69. https://doi.org/10.1016/j.eururo.2015.06.045

Article  PubMed  Google Scholar 

van den Bosch S, Alfred Witjes J (2011) Long-term Cancer-specific survival in patients with High-risk, non–muscle-invasive bladder Cancer and Tumour Progression: a systematic review. Eur Urol 60(3):493–500. https://doi.org/10.1016/j.eururo.2011.05.045

Article  PubMed  Google Scholar 

Lobo N, Hensley PJ, Bree KK et al (2022) Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder Cancer treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84–91. https://doi.org/10.1016/j.euo.2021.11.006

Article  PubMed  Google Scholar 

Ślusarczyk A, Garbas K, Pustuła P, Zapała Ł, Radziszewski P (2024) Assessing the predictive accuracy of EORTC, CUETO and EAU Risk Stratification models for High-Grade recurrence and progression after Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder Cancer. Cancers 16(9):1684. https://doi.org/10.3390/cancers16091684

Article  PubMed  PubMed Central  Google Scholar 

Chen G, Yang T, Shao Q et al (2020) Sub-staging-specific differences in Recurrence-Free, Progression-Free, and Cancer-Specific Survival for patients with T1 bladder Cancer: a systematic review and Meta-analysis. Urol Int 104(7–8):580–586. https://doi.org/10.1159/000506238

Article  PubMed  Google Scholar 

Rouprêt M, Seisen T, Compérat E et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189(6):2069–2076. https://doi.org/10.1016/j.juro.2012.11.120

Article  PubMed  Google Scholar 

Lopez-Beltran A, Raspollini MR, Hansel D et al (2024) International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer. Am J Surg Pathol.;48(1):e24-e31. https://doi.org/10.1097/PAS.0000000000002121

Cumberbatch MGK, Foerster B, Catto JWF et al (2018) Repeat Transurethral Resection in non-muscle-invasive bladder Cancer: a systematic review. Eur Urol 73(6):925–933. https://doi.org/10.1016/j.eururo.2018.02.014

Article  PubMed  Google Scholar 

Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH (2017) Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PLoS ONE 12(12):e0189354. https://doi.org/10.1371/journal.pone.0189354

Article  CAS  PubMed  PubMed Central  Google Scholar 

Volz Y, Trappmann R, Ebner B et al (2023) Upstaging after Transurethral Resection of the bladder for Non-muscle-invasive Cancer of the bladder: who is at highest risk? Urol Int 108(1):42–48. https://doi.org/10.1159/000535024

Article  CAS  PubMed  Google Scholar 

van Rhijn BWG, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61(2):378–384. https://doi.org/10.1016/j.eururo.2011.10.026

Article  PubMed  Google Scholar 

Calò B, Sanguedolce F, Falagario UG et al (2021) Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary? World J Urol 39(10):3815–3821. https://doi.org/10.1007/s00345-021-03690-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Järvinen R, Marttila T, Kaasinen E et al (2015) Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study. Eur Urol 68(4):611–617. https://doi.org/10.1016/j.eururo.2015.02.022

Article  CAS  PubMed  Google Scholar 

Nurminen P, Nummi A, Kesti O et al (2023) Comparison of Bacillus Calmette-Guérin Maintenance Therapy with monthly instillations and the Southwest Oncology Group Protocol in the treatment of non-muscle-invasive bladder Cancer. Eur Urol Focus 9(6):1000–1007. https://doi.org/10.1016/j.euf.2023.04.012

Article  PubMed  Google Scholar 

Choy B, Tretiakova M, Zynger DL (2024) What’s new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis. J Pathol Transl Med 58(1):45–48. https://doi.org/10.4132/jptm.2023.12.11

Article  PubMed  Google Scholar 

Roumiguié M, Kamat AM, Bivalacqua TJ et al (2022) International bladder Cancer Group Consensus Statement on Clinical Trial Design for patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle-invasive bladder Cancer. Eur Urol 82(1):34–46. https://doi.org/10.1016/j.eururo.2021.12.005

Article  PubMed  Google Scholar 

Contieri R, Tan WS, Grajales V et al (2024) Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int 133(6):733–741. https://doi.org/10.1111/bju.16293

Article  CAS  PubMed  Google Scholar 

Valeri M, Contieri R, Fasulo V et al (2023) Prospective validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: results from a Mono-Institutional Confirmatory Analysis in BCG treated patients. Cancers 15(3):934. https://doi.org/10.3390/cancers15030934

Article  PubMed  PubMed Central  Google Scholar 

de Jong FC, Hoedemaeker RF, Kvikstad V et al (2021) T1 substaging of nonmuscle invasive bladder Cancer is Associated with bacillus Calmette-Guérin failure and improves patient stratification at diagnosis. J Urol 205(3):701–708. https://doi.org/10.1097/JU.0000000000001422

Article  PubMed  Google Scholar 

Colombo R, Hurle R, Moschini M et al (2018) Feasibility and clinical roles of different Substaging systems at First and Second Transurethral Resection in patients with T1 high-Grade bladder Cancer. Eur Urol Focus 4(1):87–93. https://doi.org/10.1016/j.euf.2016.06.004

Article  PubMed  Google Scholar 

Gallioli A, Diana P, Fontana M et al (2022) En Bloc Versus Conventional Transurethral resection of bladder tumors: a single-center prospective randomized noninferiority trial. Eur Urol Oncol 5(4):440–448. https://doi.org/10.1016/j.euo.2022.05.001

Article  PubMed  Google Scholar 

Yuen-Chun Teoh J, Cheng CH, Tsang CF et al (2024) Transurethral En Bloc Resection Versus Standard Resection of bladder tumour: a Randomised, Multicentre, Phase 3 Trial. Eur Urol 86(2):103–111. https://doi.org/10.1016/j.eururo.2024.04.015

Article  PubMed  Google Scholar 

Gontero P, Sylvester R, Pisano F et al (2016) The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 118(1):44–52. https://doi.org/10.1111/bju.13354

Article  PubMed  Google Scholar 

Calò B, Chirico M, Fortunato F et al (2019) Is repeat transurethral resection always needed in high-Grade T1 bladder Cancer? Front Oncol 9:465. https://doi.org/10.3389/fonc.2019.00465

Article  PubMed  PubMed Central  Google Scholar 

Del Giudice F, Flammia RS, Chung BI et al (2022) Compared efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder Cancer (NMIBC): a propensity score matched analysis. Cancers 14(4):887. https://doi.org/10.3390/cancers14040887

Article  PubMed  PubMed Central  Google Scholar 

Nardelli C, Aveta A, Pandolfo SD et al (2024) Microbiome profiling in bladder Cancer patients using the First-morning urine sample. Eur Urol Open Sci 59:18–26. https://doi.org/10.1016/j.euros.2023.11.003